FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006875259> ?p ?o ?g. }

• W2006875259 endingPage "1341" @default.
• W2006875259 startingPage "1336" @default.
• W2006875259 abstract "The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin: Chiron, Emoryville, CA, USA) in stage IV metastatic renal cell carcinoma (RCC) patients undergoing nephrectomy. Eighty-four patients were enrolled on study, and then underwent nephrectomy and harvest of tumour tissue for use in autologous vaccine manufacture. Initial treatment schedule started approximately 4 weeks after surgery and consisted of six injections: once weekly for 4 weeks, then two injections biweekly (vaccines administered at weeks 1, 2, 3, 4, 6, 8), followed by restaging at or around week 10. Patients who had stable or responsive disease continued to receive vaccine, with four more vaccinations biweekly (at weeks 10, 12, 14, 16). Patients who had progressive disease at week-10 evaluation received four consecutive 5-day-per-week courses of 11 × 106 U of IL-2 subcutaneously (weeks 10, 11, 12, 13), with four doses of vitespen at 2-week intervals (at weeks 10, 12, 14, 16). At the next evaluation (week 18), patients with a complete response received two further cycles of vitespen (with IL-2 if also received during prior cycle) or until vaccine supply was exhausted. Patients with stable disease or partial response repeated their prior cycle of therapy. Disease progressors who had not yet received IL-2 began IL-2 treatment, and progressors who had already received IL-2 came off study. Of 60 evaluable patients, 2 demonstrated complete response (CR), 2 showed partial response (PR), 7 showed stable disease, and 33 patients progressed. Sixteen patients had unconfirmed stable disease. Two patients who progressed on vaccine alone experienced disease stabilisation when IL-2 was added. Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen." @default.
• W2006875259 created "2016-06-24" @default.
• W2006875259 creator A5003707661 @default.
• W2006875259 creator A5009388082 @default.
• W2006875259 creator A5017537551 @default.
• W2006875259 creator A5034148768 @default.
• W2006875259 creator A5037773281 @default.
• W2006875259 creator A5053833270 @default.
• W2006875259 creator A5058115259 @default.
• W2006875259 creator A5075015860 @default.
• W2006875259 creator A5082402405 @default.
• W2006875259 creator A5089628178 @default.
• W2006875259 date "2008-03-25" @default.
• W2006875259 modified "2023-10-08" @default.
• W2006875259 title "Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings" @default.
• W2006875259 cites W1569070916 @default.
• W2006875259 cites W1572411832 @default.
• W2006875259 cites W1928193662 @default.
• W2006875259 cites W1977007393 @default.
• W2006875259 cites W1992522933 @default.
• W2006875259 cites W1999966467 @default.
• W2006875259 cites W2018999899 @default.
• W2006875259 cites W2040675026 @default.
• W2006875259 cites W2046507292 @default.
• W2006875259 cites W2060136712 @default.
• W2006875259 cites W2060906121 @default.
• W2006875259 cites W2072861830 @default.
• W2006875259 cites W2079099131 @default.
• W2006875259 cites W2098136315 @default.
• W2006875259 cites W2105145142 @default.
• W2006875259 cites W2105984177 @default.
• W2006875259 cites W2110064348 @default.
• W2006875259 cites W2123914905 @default.
• W2006875259 cites W2136268849 @default.
• W2006875259 cites W2143813821 @default.
• W2006875259 cites W2149456801 @default.
• W2006875259 cites W2164987676 @default.
• W2006875259 cites W2165222076 @default.
• W2006875259 cites W2171469612 @default.
• W2006875259 cites W4298379398 @default.
• W2006875259 doi "https://doi.org/10.1038/sj.bjc.6604266" @default.
• W2006875259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361701" @default.
• W2006875259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18362942" @default.
• W2006875259 hasPublicationYear "2008" @default.
• W2006875259 type Work @default.
• W2006875259 sameAs 2006875259 @default.
• W2006875259 citedByCount "58" @default.
• W2006875259 countsByYear W20068752592012 @default.
• W2006875259 countsByYear W20068752592013 @default.
• W2006875259 countsByYear W20068752592014 @default.
• W2006875259 countsByYear W20068752592015 @default.
• W2006875259 countsByYear W20068752592016 @default.
• W2006875259 countsByYear W20068752592017 @default.
• W2006875259 countsByYear W20068752592018 @default.
• W2006875259 countsByYear W20068752592019 @default.
• W2006875259 countsByYear W20068752592020 @default.
• W2006875259 countsByYear W20068752592021 @default.
• W2006875259 countsByYear W20068752592022 @default.
• W2006875259 crossrefType "journal-article" @default.
• W2006875259 hasAuthorship W2006875259A5003707661 @default.
• W2006875259 hasAuthorship W2006875259A5009388082 @default.
• W2006875259 hasAuthorship W2006875259A5017537551 @default.
• W2006875259 hasAuthorship W2006875259A5034148768 @default.
• W2006875259 hasAuthorship W2006875259A5037773281 @default.
• W2006875259 hasAuthorship W2006875259A5053833270 @default.
• W2006875259 hasAuthorship W2006875259A5058115259 @default.
• W2006875259 hasAuthorship W2006875259A5075015860 @default.
• W2006875259 hasAuthorship W2006875259A5082402405 @default.
• W2006875259 hasAuthorship W2006875259A5089628178 @default.
• W2006875259 hasBestOaLocation W20068752591 @default.
• W2006875259 hasConcept C126322002 @default.
• W2006875259 hasConcept C141071460 @default.
• W2006875259 hasConcept C142724271 @default.
• W2006875259 hasConcept C146357865 @default.
• W2006875259 hasConcept C151730666 @default.
• W2006875259 hasConcept C22070199 @default.
• W2006875259 hasConcept C2776694085 @default.
• W2006875259 hasConcept C2777472916 @default.
• W2006875259 hasConcept C2778822529 @default.
• W2006875259 hasConcept C2780091579 @default.
• W2006875259 hasConcept C2780227381 @default.
• W2006875259 hasConcept C71924100 @default.
• W2006875259 hasConcept C86803240 @default.
• W2006875259 hasConceptScore W2006875259C126322002 @default.
• W2006875259 hasConceptScore W2006875259C141071460 @default.
• W2006875259 hasConceptScore W2006875259C142724271 @default.
• W2006875259 hasConceptScore W2006875259C146357865 @default.
• W2006875259 hasConceptScore W2006875259C151730666 @default.
• W2006875259 hasConceptScore W2006875259C22070199 @default.
• W2006875259 hasConceptScore W2006875259C2776694085 @default.
• W2006875259 hasConceptScore W2006875259C2777472916 @default.
• W2006875259 hasConceptScore W2006875259C2778822529 @default.
• W2006875259 hasConceptScore W2006875259C2780091579 @default.
• W2006875259 hasConceptScore W2006875259C2780227381 @default.
• W2006875259 hasConceptScore W2006875259C71924100 @default.
• W2006875259 hasConceptScore W2006875259C86803240 @default.
• W2006875259 hasIssue "8" @default.
• W2006875259 hasLocation W20068752591 @default.

• next